CG Oncology, Inc. Common stock (CGON) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| License and Collaboration Revenue | 14K | FY2026-Q1 |
| Confirmed Complete Responses at 24 Months (BOND-003 Cohort C) | 46.00 | FY2025-Q3 |
| Twelve-Month Responders Remaining Disease Free at 24 Months (BOND-003 Cohort C) | 90.00 percent | FY2025-Q3 |
| Complete Response Rate at Any Time (Cretostimogene Monotherapy, BOND-003) | 75.50 percent | FY2025-Q2 |
| Median Duration of Response Exceeded | 28.00 | FY2025-Q2 |
| Efficacy-Evaluable Patients (BOND-003 Cohort C) | 110.00 | FY2025-Q2 |
| Patients Completing All Expected Treatments | 97.30 percent | FY2025-Q2 |
Back to CGON overview · CGON earnings · CGON holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.